Document is current
Any future updates will be listed below
-
Authors
Greteman, Breanna B.
Cole, Allison
Charlton, Mary E.
Shannon, Jackilen
Kepka, Deanna
Paskett, Electra D.
Borrayo, Evelinn A.
Studts, Jamie L.
Thompson, Hayley S.
Scarinci, Isabel
Hinton, Lynn Chollet
Chrischilles, Elizabeth A.
Garcia-Auguste, Crystal J.
Christini, Kaila
Aker, Heather
Plascak, Jesse J.
Harper, Felicity W. K.
Baskin, Monica L.
Bae, Sejong
Pandya, Vishruti
Kim, Young-il
Faseru, Babalola
Befort, Christie
Kuo, Hanluen
Dignan, Mark
Canedo, Juan
Champion, Victoria
Drake, Bettina F.
Davis, Kia L.
Friedman, Debra L.
Elsaid, Mohamed I.
Mama, Scherezade K.
Cohn, Wendy F.
-
Funding
Funding for this research was provided by:
Holden Comprehensive Cancer Center, University of Iowa (3P30CA086862)
Knight Cancer Institute, Oregon Health and Science University (P30 CA069533-23S3)
Huntsman Cancer Institute, University of Utah (P30CA042014)
Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (P30 CA016058)
Center for Clinical and Translational Science, Ohio State University (UL1TR002733)
Cancer Center, University of Colorado (P30CA046934)
Barbara Ann Karmanos Cancer Institute (P30CA022453)
Comprehensive Cancer Center, University of Alabama at Birmingham (P30CA013148-48)
Cancer Center, University of Kansas (CA168524-07S2)
Markey Cancer Center, University of Kentucky (P30 CA177558)
Alvin J. Siteman Cancer Center (P30CA091842-18S2)
Vanderbilt-Ingram Cancer Center (P30CA068485)
University of Texas MD Anderson Cancer Center (P30CA016672)
UVA Cancer Center (P30CA044579)
- License Information
-
More Information
Article History
Received: 24 April 2024
Accepted: 19 December 2024
First Online: 9 January 2025
Declarations
:
: Written informed consent was obtained from all participants via an informed consent document included in survey packets. The informed consent document explained the purpose of the survey, how the data will be stored and analyzed, that their de-identified data may be analyzed for publication, and any benefits and risks associated with survey participation. Research was performed in accordance with the Declaration of Helsinki. Institutional Review Board (IRB) approval for this study was received from each individual site. The following sites were approved after full IRB review: Colorado Multiple IRB (Study ID PAM020-2), and Vanderbilt IRB (IRB #190235). To note, Colorado’s survey was conducted as an extension of an existing survey; thus, the approval for Colorado’s added COVID survey is shown as an amendment. The following sites received expedited review or were ruled exempt from full IRB review: University of Iowa (#IRB00000099), University of Virginia IRB for Health Sciences Research (IRB-HSR #22747), Wayne State University IRB (IRB #20-05-2219-B3), University of Alabama at Birmingham IRB (IRB #00000196/#00000726), Oregon Health & Science University IRB (IRB #300002135), and Ohio State University Cancer IRB (Study #2020C0081). Data use agreements were obtained from each site to transmit de-identified data to the coordinating center at the University of Alabama at Birmingham (UAB).
: Written consent was received via an informed consent document included in survey packets. The informed consent document explained the purpose of the survey, how the data will be stored and analyzed, that their de-identified data may be analyzed for publication, and any benefits and risks associated with survey participation.
: Deanna Kepka is the Principal Investigator of two Merck Investigator Studies Program (MISP) Awards to Huntsman Cancer Institute at the University of Utah. Electra Paskett is the MPI on grants to the institution from Merck Foundation, Pfizer, Genentech, and Guardant Health and is an advisor for Glaxo Smith Kline. Jamie Studts provides consultation to Genentech and the J&J Lung Cancer Initiative. Monica Baskin is an advisor to Janssen Global Services, LLC; none are related to this work. The rest of the authors (BBG, AC, MEC, JS, EAB, HT, IS, LCH, EAC, CJGA, KC, HA, JJP, FWKH, SB, VP, YK, BF, CB, HK, MD, JC, VC, BFD, KLD, DLF, MIE, SKM, and WFC) declare they have no competing interest(s).
